Virus-like particles containing the extracellular domain of G protein in combination with a CTL peptide of M2 elicit protection against respiratory syncytial virus infection without pulmonary disease.

ABSTRACT:

Background and aims

Respiratory syncytial virus (RSV) is a major respiratory pathogen afflicting both infants and the elderly. Although three RSV vaccines have been approved for adults over the age of 60 or pregnant individuals, there are ongoing efforts to develop novel vaccines against RSV infection. This study was designed to develop and evaluate virus-like particles (VLPs) as potential RSV subunit vaccine candidates, with the goal of balancing immunogenicity, protective efficacy, and safety.

Methods

Two types of VLPs were constructed using a recombinant baculovirus (rBV)-insect cell expression system: G_ECD-VLPs (containing the extracellular domain [G_ECD] of RSV G protein) and G_ECD/M2_82-90-VLPs (containing GECD fused with the CT

SUBMITTER: Qin H 

PROVIDER: S-EPMC12463943 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature